Abstract
Aging can lead to decline in cognition, notably due to neurodegenerative processes overwhelming the brain over time. As people live longer, numerous concerns are rightfully raised toward long-term slowly incapacitating diseases with no cure, such as Alzheimer's disease. Since the early 2000's, the role of neuroinflammation has been scrutinized for its potential role in the development of diverse neurodegenerative diseases notably because of its slow onset and chronic nature in aging. Despite the lack of success yet, treatment of chronic neuroinflammation could help alleviate process implicated in neurodegenerative disease. A growing number of studies including our own have aimed at the endocannabinoid system and unfolded unique effects of this system on neuroinflammation, neurogenesis and hallmarks of Alzheimer's disease and made it a reasonable target in the context of normal and pathological brain aging.
Highlights
Aging can lead to decline in cognition, notably due to neurodegenerative processes overwhelming the brain over time
It seems clear that neuroinflammation plays an important role in Alzheimer’s disease (AD) and that it may even influence disease progression very early on, especially as AD is diagnosed rather late while the mechanisms leading to neurodegeneration are already in motion probably decades before
Most studies looking at the modulation of neuroinflammation using cannabinoids have mainly focused on CB2 receptors as they are mostly expressed on microglial cells
Summary
Aging can lead to decline in cognition, notably due to neurodegenerative processes overwhelming the brain over time. The disease is characterized by a slow but progressive loss of cognitive functions associated with neurodegeneration, as well as an important neuroinflammation [2]. If inflammatory processes are well known to accompany tissue damage in many neurodegenerative diseases as Parkinson’s [10] or amyotrophic lateral sclerosis [11], AD’s progression seems to be tightly linked to chronic inflammation.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
